From: Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
Total
Grade I
Grade II
Grade III
Grade IV
Number (%)
First-line treatment
30 (57.7)
10 (33.3)
3 (10)
2 (6.7)
0 (0)
Second-line treatment
22 (42.3)
6 (27.3)
2 (9.1)
1 (4.5)